Abiopharma

🔍 Martin James Joseph (Executive)

Company: Cocrystal Pharma, Inc. (COCP)

Report Date: 2026-01-09

Detailed Transactions and Holdings:

• Acquired 49,229 shares of Stock Options (Right to Buy) at $1.1 per share (Derivative)
  Date: 2026-01-09 | Code: A | Expires: 2036-01-09 | equity_swap_involved: 0 | shares_owned_after: 49,229.00 | transaction_form_type: 4 | Footnotes: F1, F1

Footnotes:

• F1: The grant of the Issuer's non-qualified stock options was exempt from Section 16(b) of the Securities Exchange Act of 1934 by virtue of Rule 16b-3 promulgated thereunder, as it was approved by the Issuer's Compensation Committee of the Board of Directors. The non-qualified stock options are granted under the Issuer's 2025 Equity Incentive Plan and the exercisability shall be subject to execution of the Issuer's form of Non-Qualified Stock Option Agreement. The non-qualified stock options shall vest as follows: one-half shall vest and become exercisable on January 9, 2027 and the remaining half shall vest and become exercisable in eight equal quarterly installments commencing on March 31, 2027, subject to the Reporting Person continuing to serve as an officer of the Issuer on each applicable vesting date.